|
Market Closed -
Nasdaq
16:00:00 2026-08-18 EDT
|
5-day change | 1st Jan Change | ||
| 3.520 USD | +0.28% |
|
+12.46% | -15.38% |
Company Valuation: Galectin Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 122.8 | 67.15 | 102.7 | 80.96 | 268.2 | 355 | - |
| Change | - | -45.33% | 52.89% | -21.14% | 231.27% | 32.36% | - |
| Enterprise Value (EV) | 122.8 | 67.15 | 102.7 | 80.96 | 268.2 | 355 | 355 |
| Change | - | -45.33% | 52.89% | -21.14% | 231.27% | 32.36% | 0% |
| P/E | -3.98x | -1.74x | -2.24x | -1.7x | -8.67x | -11.7x | -15.3x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | -0.1x | -0.2x | -0.63x | 0.2x | 0.3x | 0.7x |
| Capitalization / Revenue | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | -20.3x | -18.4x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -20.3x | -18.4x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.52 | -0.65 | -0.74 | -0.76 | -0.48 | -0.3 | -0.23 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | - | -17.5 | -19.3 |
| EBIT 1 | -30.18 | -38.35 | -38.07 | -42.43 | -20.08 | -17.5 | -19.3 |
| Net income 1 | -30.7 | -38.87 | -44.8 | -47.2 | -30.97 | -24.9 | -19.3 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 2.070 | 1.130 | 1.660 | 1.290 | 4.160 | 3.520 | 3.520 |
| Nbr of stocks (in thousands) | 59,341 | 59,426 | 61,849 | 62,762 | 64,473 | 100,850 | - |
| Announcement Date | 3/31/22 | 3/30/23 | 3/29/24 | 3/31/25 | 3/31/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -11.73x | - | - | - | 355M | |
| 33.23x | 5.94x | 17.65x | 0.97% | 48.63B | |
| -22.42x | 307.68x | -22.84x | -.--% | 46.3B | |
| 48.36x | 5.61x | 30.68x | -.--% | 41.97B | |
| 30.91x | 3.06x | 13.22x | -.--% | 39.51B | |
| 29.75x | 8.57x | 21.59x | 0.39% | 31.75B | |
| 33.57x | 5.5x | 24.97x | -.--% | 16.48B | |
| 23.22x | 2.04x | 8.81x | 1.16% | 14B | |
| 74.7x | 3.95x | 15.31x | -.--% | 13.33B | |
| Average | 26.62x | 42.79x | 13.67x | 0.31% | 28.03B | |
| Weighted average by Cap. | 26.33x | 60.86x | 12.05x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- GALT Stock
- Valuation Galectin Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
